{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:52:12Z","timestamp":1789051932894,"version":"build-2803163510"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":427,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004095","name":"Kyowa Hakko Kirin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004095","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Blood levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT-proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This post hoc analysis stemmed from the oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN) trial, a large prospective study involving patients with non-dialysis kidney disease experiencing anaemia. The Pearson correlation coefficient was employed to examine the association of baseline NT-proBNP level with renal function or anaemia. Longitudinal assessment of the association of baseline blood NT-proBNP levels with cardiovascular outcomes (cardiac death, acute coronary syndrome, hospitalization due to heart failure or fatal arrhythmia) and renal outcomes [the initiation of maintenance dialysis, kidney transplantation, a 50% decrease in the estimated glomerular filtration rate (eGFR) or an eGFR of \u22646 mL\/min\/1.73 m2] was conducted by using restricted cubic spline analysis and Cox proportional hazard model analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, this study included 1484 patients [mean age, 70.2 \u00b1 11.8 years; women, 40.6%; eGFR, 20.3 \u00b1 9.6 mL\/min\/1.73 m2; haemoglobin (Hb) level, 9.8 \u00b1 0.9 g\/dL]. Baseline NT-proBNP levels were a median of 496.0 pg\/mL [inter-quartile range: 235.0\u20131090.0 pg\/mL]. A weak association existed between NT-proBNP levels, on a logarithmic scale, and eGFR (r = \u22120.131, P &amp;lt; 0.001) or Hb levels (r = \u22120.182, P &amp;lt; 0.001) at baseline. During 2.29 \u00b1 0.89 years, 92 cardiovascular and 573 renal events were recorded. After adjusting for potential confounders such as eGFR and blood Hb level, a nonlinear relationship existed between blood NT-proBNP levels and cardiorenal outcomes. Patients with a baseline NT-proBNP level \u22651000 and 500\u20131000 pg\/mL exhibited a greater risk for cardiovascular outcomes than did patients with an NT-proBNP level &amp;lt;250 pg\/mL {hazard ratio [HR] = 8.10 [95% confidence interval (CI), 2.80\u201323.40] and 3.35 [95% CI, 1.10\u201310.18], respectively}. These patients also exhibited a moderate risk for renal outcomes [HR = 1.77 (95% CI, 1.36\u20132.31) and 1.54 (95% CI, 1.19\u20132.00), respectively].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NT-proBNP provides prognostic insights into cardiovascular and renal outcomes among patients with advanced chronic kidney disease experiencing anaemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15042","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T01:44:56Z","timestamp":1734572696000},"page":"848-858","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["N-Terminal Pro-Brain Natriuretic Peptide and Cardiorenal Outcome in Patients with Anaemia in Chronic Kidney Disease"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8415-7889","authenticated-orcid":false,"given":"Hiroshi","family":"Nishi","sequence":"first","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Sofue","sequence":"additional","affiliation":[{"name":"Department of Cardiorenal and Cerebrovascular Medicine, Faculty of Medicine, Kagawa University , Takamatsu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuo","family":"Kagimura","sequence":"additional","affiliation":[{"name":"Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe , Kobe ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[{"name":"Division of Clinical Nephrology and Rheumatology, Kidney Research Center, Niigata University Graduate School of Medical and Dental Sciences , Niigata ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"2026021804043798500_ehf215042-bib-0001","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1172\/JCI115146","article-title":"Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide","volume":"87","author":"Mukoyama","year":"1991","journal-title":"J Clin Invest"},{"key":"2026021804043798500_ehf215042-bib-0002","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ejhf.2848","article-title":"Natriuretic peptides: Role in the diagnosis and management of heart failure: A scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society","volume":"25","author":"Tsutsui","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026021804043798500_ehf215042-bib-0003","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMoa031994","article-title":"Plasma natriuretic peptide levels and the risk of cardiovascular events and death","volume":"350","author":"Wang","year":"2004","journal-title":"N Engl J Med"},{"key":"2026021804043798500_ehf215042-bib-0004","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1161\/CIRCULATIONAHA.109.884866","article-title":"B-type natriuretic peptides and cardiovascular risk: Systematic review and meta-analysis of 40 prospective studies","volume":"120","author":"Di Angelantonio","year":"2009","journal-title":"Circulation"},{"key":"2026021804043798500_ehf215042-bib-0005","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021804043798500_ehf215042-bib-0006","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1373\/49.8.1337","article-title":"Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care","volume":"49","author":"Alehagen","year":"2003","journal-title":"Clin Chem"},{"key":"2026021804043798500_ehf215042-bib-0007","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1053\/j.ajkd.2005.06.017","article-title":"B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: Relationship to renal function and left ventricular hypertrophy","volume":"46","author":"Vickery","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"2026021804043798500_ehf215042-bib-0008","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1309\/M7AAXA0J1THMNCDF","article-title":"Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease","volume":"126","author":"Austin","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"2026021804043798500_ehf215042-bib-0009","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1309\/AJCP60HTPGIGFCNK","article-title":"The effect of renal dysfunction on BNP, NT-proBNP, and their ratio","volume":"133","author":"Srisawasdi","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"2026021804043798500_ehf215042-bib-0010","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/1471-2369-14-117","article-title":"B-type natriuretic peptide versus amino terminal pro-B type natriuretic peptide: Selecting the optimal heart failure marker in patients with impaired kidney function","volume":"14","author":"Jafri","year":"2013","journal-title":"BMC Nephrol"},{"key":"2026021804043798500_ehf215042-bib-0011","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/eci.12234","article-title":"Kidney function crucially affects B-type natriuretic peptide (BNP), N-terminal proBNP and their relationship","volume":"44","author":"Takase","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"2026021804043798500_ehf215042-bib-0012","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1253\/circrep.CR-19-0063","article-title":"Renal clearance of N-terminal pro-brain natriuretic peptide is markedly decreased in chronic kidney disease","volume":"1","author":"Tsutamoto","year":"2019","journal-title":"Circ Rep"},{"key":"2026021804043798500_ehf215042-bib-0013","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.amjcard.2003.12.062","article-title":"Relation of anemia to diastolic heart failure and the effect on outcome","volume":"93","author":"Brucks","year":"2004","journal-title":"Am J Cardiol"},{"key":"2026021804043798500_ehf215042-bib-0014","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1042\/CS20040349","article-title":"Blood haemoglobin is an independent predictor of B-type natriuretic peptide (BNP)","volume":"109","author":"Wold Knudsen","year":"2005","journal-title":"Clin Sci (Lond)"},{"key":"2026021804043798500_ehf215042-bib-0015","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.cccn.2005.03.009","article-title":"Effect of anemia on plasma concentrations of NT-proBNP","volume":"358","author":"Willis","year":"2005","journal-title":"Clin Chim Acta"},{"key":"2026021804043798500_ehf215042-bib-0016","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.ejheart.2007.06.005","article-title":"Association between anaemia and N-terminal pro-B-type natriuretic peptide (NT-proBNP): Findings from the Heart and Soul Study","volume":"9","author":"Desai","year":"2007","journal-title":"Eur J Heart Fail"},{"key":"2026021804043798500_ehf215042-bib-0017","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.semnephrol.2006.06.001","article-title":"Pathogenesis of renal anemia","volume":"26","author":"Nangaku","year":"2006","journal-title":"Semin Nephrol"},{"key":"2026021804043798500_ehf215042-bib-0018","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","article-title":"Hypoxia-inducible factor activators in renal anemia: Current clinical experience","volume":"26","author":"Sanghani","year":"2019","journal-title":"Adv Chronic Kidney Dis"},{"key":"2026021804043798500_ehf215042-bib-0019","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1182\/blood.2019004330","article-title":"How I treat renal anemia","volume":"136","author":"Fishbane","year":"2020","journal-title":"Blood"},{"key":"2026021804043798500_ehf215042-bib-0020","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236132","article-title":"Prevalence of anemia in patients with chronic kidney disease in Japan: A nationwide, cross-sectional cohort study using data from the Japan Chronic Kidney Disease Database (J-CKD-DB)","volume":"15","author":"Sofue","year":"2020","journal-title":"PLoS ONE"},{"key":"2026021804043798500_ehf215042-bib-0021","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1373\/clinchem.2006.083170","article-title":"B-type natriuretic peptide concentrations predict the progression of nondiabetic chronic kidney disease: The Mild-to-Moderate Kidney Disease Study","volume":"53","author":"Spanaus","year":"2007","journal-title":"Clin Chem"},{"key":"2026021804043798500_ehf215042-bib-0022","doi-asserted-by":"publisher","first-page":"3546","DOI":"10.1093\/ndt\/gfn341","article-title":"Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population","volume":"23","author":"Vickery","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2026021804043798500_ehf215042-bib-0023","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159914","article-title":"Clinical value of natriuretic peptides in predicting time to dialysis in stage 4 and 5 chronic kidney disease patients","volume":"11","author":"Sundqvist","year":"2016","journal-title":"PLoS ONE"},{"key":"2026021804043798500_ehf215042-bib-0024","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1159\/000496238","article-title":"NT-proBNP in the prognosis of death or need for renal replacement therapy in patients with stage 3\u20135 chronic kidney disease","volume":"9","author":"Gromadzinski","year":"2019","journal-title":"Cardiorenal Med"},{"key":"2026021804043798500_ehf215042-bib-0025","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1053\/j.ajkd.2011.05.020","article-title":"Association between cardiac biomarkers and the development of ESRD in patients with type 2 diabetes mellitus, anemia, and CKD","volume":"58","author":"Desai","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"2026021804043798500_ehf215042-bib-0026","doi-asserted-by":"publisher","first-page":"3885","DOI":"10.1093\/ndt\/gfs365","article-title":"Plasma B-type natriuretic peptide level predicts kidney prognosis in patients with predialysis chronic kidney disease","volume":"27","author":"Yasuda","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2026021804043798500_ehf215042-bib-0027","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1097\/HJH.0000000000000847","article-title":"Plasma B-type natriuretic peptide concentration is independently associated with kidney function decline in Japanese patients with chronic kidney disease","volume":"34","author":"Yoshitomi","year":"2016","journal-title":"J Hypertens"},{"key":"2026021804043798500_ehf215042-bib-0028","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1007\/s10157-017-1427-4","article-title":"Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: Renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN trial)","volume":"22","author":"Kato","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2026021804043798500_ehf215042-bib-0029","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10157-020-01969-7","article-title":"Initial responsiveness to darbepoetin alfa and its contributing factors in non-dialysis chronic kidney disease patients in Japan","volume":"25","author":"Hayashi","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"2026021804043798500_ehf215042-bib-0030","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277921","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study","volume":"17","author":"Narita","year":"2022","journal-title":"PLoS ONE"},{"key":"2026021804043798500_ehf215042-bib-0031","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"2026021804043798500_ehf215042-bib-0032","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2215\/CJN.01110306","article-title":"Hemoglobin level variability: Associations with comorbidity, intercurrent events, and hospitalizations","volume":"1","author":"Ebben","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026021804043798500_ehf215042-bib-0033","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.ekir.2023.06.004","article-title":"Infectious risk and variability of hemoglobin level in patients undergoing hemodialysis","volume":"8","author":"Nishi","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026021804043798500_ehf215042-bib-0034","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jacc.2009.02.095","article-title":"N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: Results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial","volume":"55","author":"Lainchbury","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"2026021804043798500_ehf215042-bib-0035","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jama.2017.10565","article-title":"Effect of natriuretic peptide-guided therapy on hospitalization or cardiovascular mortality in high-risk patients with heart failure and reduced ejection fraction: A randomized clinical trial","volume":"318","author":"Felker","year":"2017","journal-title":"JAMA"},{"key":"2026021804043798500_ehf215042-bib-0036","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCULATIONAHA.117.029882","article-title":"NT-proBNP (N-terminal pro-B-type natriuretic peptide)-guided therapy in acute decompensated heart failure: PRIMA II randomized controlled trial (can NT-proBNP-guided therapy during hospital admission for acute decompensated heart failure reduce mortality and readmissions?)","volume":"137","author":"Stienen","year":"2018","journal-title":"Circulation"},{"key":"2026021804043798500_ehf215042-bib-0037","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1744-9987.2010.00836.x","article-title":"2008 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease","volume":"14","author":"Tsubakihara","year":"2010","journal-title":"Ther Apher Dial"},{"key":"2026021804043798500_ehf215042-bib-0038","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s41100-017-0114-y","article-title":"2015 Japanese Society for Dialysis Therapy: Guidelines for renal anemia in chronic kidney disease","volume":"3","author":"Yamamoto","year":"2017","journal-title":"Renal Replace Ther"},{"key":"2026021804043798500_ehf215042-bib-0039","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of anemia in chronic kidney disease: Beyond erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv Ther"},{"key":"2026021804043798500_ehf215042-bib-0040","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","article-title":"Controversies in optimal anemia management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference","volume":"99","author":"Babitt","year":"2021","journal-title":"Kidney Int"},{"key":"2026021804043798500_ehf215042-bib-0041","doi-asserted-by":"publisher","first-page":"ii1-47","DOI":"10.1093\/ndt\/gfh1032","article-title":"Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"2026021804043798500_ehf215042-bib-0042","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap","year":"2021","journal-title":"Nephrology (Carlton)"},{"key":"2026021804043798500_ehf215042-bib-0043","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/14656566.2024.2378903","article-title":"A spotlight on using HIF-PH inhibitors in renal anemia","volume":"25","author":"Odawara","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026021804043798500_ehf215042-bib-0044","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1681\/ASN.2019060582","article-title":"Prolyl hydroxylase domain inhibitor protects against metabolic disorders and associated kidney disease in obese type 2 diabetic mice","volume":"31","author":"Sugahara","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2026021804043798500_ehf215042-bib-0045","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0255022","article-title":"A small-molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase improves obesity, nephropathy and cardiomyopathy in obese ZSF1 rats","volume":"16","author":"Signore","year":"2021","journal-title":"PLoS ONE"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/2\/848\/66953098\/eschf_12_2_848.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/2\/848\/66953098\/eschf_12_2_848.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:04:42Z","timestamp":1771405482000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/2\/848\/8487983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":45,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,18]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15042","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,12,18]]},"assertion":[{"value":"2024-05-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}